Department of Intensive Care Unit, The First Affiliated Hospital of Jiamusi University.
Department of Intensive Care Unit, Jiamusi Traditional Chinese Medicine Hospital.
Medicine (Baltimore). 2021 Apr 2;100(13):e25086. doi: 10.1097/MD.0000000000025086.
Pulmonary embolism (PE) is a life-threatening disease, which accounts for the major type of venous thromboembolism. Currently, there is limited understanding and management for PE. Rivaroxaban is reported to treat patients with PE. However, there is still insufficient evidence on rivaroxaban for the treatment of Chinese patients with acute PE. Thus, this retrospective study investigated the benefits and safety of rivaroxaban for Chinese patients with acute PE.A total of 72 Chinese patient cases with acute PE were analyzed in this study. Of these, 36 cases who received rivaroxaban mono-therapy were assigned to the treatment group, while the remaining 36 cases who received standard therapy were assigned to the control group. The benefits were assessed by the duration of hospital stay, treatment satisfaction, and safety.After treatment, rivaroxaban mono-therapy showed better benefits in decreasing the duration of hospital stay (P < .01), increasing treatment satisfaction (P < .01), and reducing mild bleeding (P = .02) in Chinese patients with acute PE, than standard therapy.The results of this study indicated that rivaroxaban may provide more benefits than the standard therapy for Chinese patients with acute PE. Future studies are still needed to warrant the current results.
肺栓塞（PE）是一种危及生命的疾病，是静脉血栓栓塞症的主要类型。目前，人们对 PE 的认识和管理有限。利伐沙班被报道可用于治疗 PE 患者。然而，对于中国急性 PE 患者使用利伐沙班的治疗仍缺乏足够的证据。因此，这项回顾性研究调查了利伐沙班治疗中国急性 PE 患者的疗效和安全性。
本研究共分析了 72 例中国急性 PE 患者病例。其中，36 例接受利伐沙班单药治疗的患者被分配到治疗组，而其余 36 例接受标准治疗的患者被分配到对照组。通过住院时间、治疗满意度和安全性来评估疗效。
治疗后，与标准治疗相比，利伐沙班单药治疗在中国急性 PE 患者中能更显著地降低住院时间（P<0.01）、提高治疗满意度（P<0.01）和减少轻度出血（P=0.02）。
本研究结果表明，利伐沙班可能为中国急性 PE 患者提供比标准治疗更多的益处。仍需要进一步的研究来证实目前的结果。
